Caspofungin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Caspofungin
- Pharmacist Assessment Report
- Caspofungin: From Esophageal Candidiasis and Candidemia to Gastrin Secretion Abnormality
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Caspofungin: From Esophageal Candidiasis and Candidemia to Gastrin Secretion Abnormality
One-Sentence Summary
Caspofungin is an echinocandin antifungal originally used to treat esophageal candidiasis and candidemia. The TxGNN model ranks gastrin secretion abnormality as its top predicted new use, but this is a computational prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Esophageal candidiasis; candidemia |
| Predicted New Indication | Gastrin secretion abnormality |
| TxGNN Prediction Score | 0.9944 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Caspofungin inhibits beta-(1,3)-D-glucan synthase, an enzyme that fungi need to build their cell wall. Human cells do not have this enzyme, which is why the drug is selective for fungal infections such as Candida.
Esophageal candidiasis and candidemia are fungal infections. Gastrin secretion abnormality is a disorder of a human digestive hormone. We found no plausible mechanistic link between blocking fungal glucan synthesis and regulating gastrin. The very high score (0.9944) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. With no trials or publications behind it, this prediction should be treated as a computational hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Caspofungin has 20 valid single-ingredient registrations in India, all injectable vials. The five below are examples. The approved indication text is not listed for these registrations.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 112805 | Ibicasp 50mg Injection | Vial of 1 injection | Indiabulls Pharmaceutical Ltd |
| 29267 | Brufungin 50 Injection | Vial of 1 injection | Brawn Laboratories Ltd |
| 52244 | Caspercid 50mg Injection | Vial of 1 injection | Sanofi India Ltd |
| 44817 | Casfungen 50mg Injection | Vial of 1 injection | Chandra Bhagat Pharma Pvt Ltd |
| 106113 | Hospicasp 70mg Injection | Vial of 1 injection | Alkem Laboratories Ltd |
Safety Considerations
- Disease associations from the knowledge graph (these come from graph relationships, not from package insert text): liver disease, gallbladder disease, potassium deficiency disease.
- Drug Interactions: 81 interacting drugs were identified.
- Major: dexamethasone.
- Moderate: naltrexone.
- The rest have no severity rating. They include pantoprazole, omeprazole, lansoprazole, simvastatin, amphotericin B, prednisone, hydrocortisone and potassium chloride.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has the highest score but no clinical or literature support. It also has no plausible mechanism, since caspofungin acts on a fungal enzyme and has no known role in gastrin regulation. It remains at evidence level L5.
To proceed, the following is needed:
- Any mechanistic or preclinical evidence linking caspofungin to gastrin regulation
- Package insert warnings and contraindications for the Indian products
- Detailed mechanism of action data from a curated source
Note on other candidates: Other predictions in the same list have much stronger support than this one. The best is neonatal candidiasis (evidence level L2), with two Phase 2 trials (NCT00330395, completed, n=16; NCT01945281, terminated, n=51) and a pediatric echinocandin meta-analysis. It would be classed as Proceed with Guardrails: confirm neonatal dosing and PK, monitor liver function, and clarify why the randomized trial was terminated. Neonatal candidiasis is an extension of the approved candidemia use, not a new mechanism, so it would be a more productive focus for further evaluation than the top-ranked prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.